Banbrytande cancerstudier: Slipp kemoterapi, dess biverkningar och bli botad utan biv

Abstract Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer stem cells.

Conclusion
In this prospective real-world cohort, the combination of ivermectin and mebendazole was
associated with high proportions of self-reported clinical benefit, with nearly half of participants
declaring tumor regression or no current evidence of disease across a heterogeneous population
of cancer types. These findings, observed alongside favorable tolerability and strong adherence,
support the biological plausibility suggested by preclinical data, indicating this combination may
offer therapeutic potential as an adjunctive or repurposed strategy in oncology. However, given
the observational design, reliance on self-reported outcomes, and potential for confounding,
these results should be interpreted as hypothesis-generating. Rigorous randomized, double blind,
placebo-controlled trials are urgently needed to validate safety and efficacy, clarify optimal
dosing strategies, and determine the role of this combination across specific cancer types.